On August 6, 2020, the Board of Directors (the “Board”) of Eidos Therapeutics, Inc. (the “Company”) appointed Suzanne Sawochka Hooper and Douglas “Duke” Rohlen, as members of the Board, effective August 6, 2020. Upon joining the Board, Ms. Hooper and Mr. Rohlen became members of the Board’s audit committee, replacing Eric Aguiar and Rajeev Shah, with Mr. Rohlen as Chair. Suzanne Sawochka Hooper previously served as executive vice president and general counsel at Jazz Pharmaceuticals, Inc. from March 2012 through February 2019. Prior to joining Jazz, Ms. Hooper was a partner at the law firm of Cooley LLP, representing a broad range of companies and investors in the life sciences industry and working with boards of directors and senior management teams on complex legal and strategic matters, including mergers and acquisitions. Ms. Hooper has been a member of the Board of Directors of NGM Biopharmaceuticals, Inc. since 2018. Douglas “Duke” Rohlen is the founder and Chief Executive Officer of Ajax Health, a holding company that funds and operates innovative healthcare companies, where he has served since May 2017. Prior to that, from December 2013 to May 2019, he co-founded and served as the chairman and Chief Executive Officer of EPIX Therapeutics, which was acquired by Medtronic in 2019. He also co-founded and served as Chief Executive Officer of Spirox, which was acquired by Entellus in 2017; and CV Ingenuity, which was acquired by Covidien in 2013. Previously Mr. Rohlen was the president of Foxhollow Technologies. On August 6, 2020, Eric Aguiar and Rajeev Shah delivered their resignations from the Board, effective upon the appointments of Ms. Hooper and Mr. Rohlen. Dr. Aguiar and Mr. Shah had also served as members of the Board’s audit committee. There were no disagreements between Dr. Aguiar, Mr. Shah and the Company on any matter relating to the Company’s operations, policies or practices which resulted in their resignation. Ms. Hooper and Mr. Rohlen were appointed to the vacancies on the Board created by Dr. Aguiar’s and Mr. Shah’s resignations.